XML 81 R59.htm IDEA: XBRL DOCUMENT v3.20.4
Collaboration and Profit-Sharing Agreements - Summary of Agreements (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 8 Months Ended 12 Months Ended 15 Months Ended
Mar. 31, 2020
item
Nov. 30, 2019
USD ($)
item
Jul. 31, 2018
USD ($)
May 31, 2018
USD ($)
item
Mar. 31, 2017
USD ($)
May 31, 2015
USD ($)
item
Dec. 31, 2020
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Jul. 31, 2017
USD ($)
item
Revenue recognized             $ 5,767   $ 92,302      
Deferred revenue             94,927   94,927 $ 186,721    
Deferred revenue, long-term             73,984   73,984 163,207    
Research and development                 157,996 96,898 $ 90,654  
Juno Therapeutics                        
Total transaction price               $ 12,300     40,700  
Allocable arrangement consideration - R&D Services Unit of Accounting             10,700   10,700      
Allocable arrangement consideration - Material rights             30,000   30,000      
Allergan                        
Deferred revenue             0   0      
One time payment to acquire the license         $ 25,000              
Collaboration and License Agreement | Juno Therapeutics                        
Number of research areas | item           3            
Agreement term           5 years            
Upfront fee received           $ 25,000            
Number of milestones related to technical progress | item                       2
Potential fee receivable for each gene target licensed           $ 2,500            
Number of additional licenses | item           3            
Transaction price research and development expenses funding                     2,900  
Transaction price milestone payment received                     7,700  
Milestone payment received under license agreement                       $ 2,500
Amended Collaboration and License Agreement | Juno Therapeutics                        
Number of research areas | item       4                
Additional upfront fee received       $ 5,000                
Number of milestones related to technical progress | item       2                
Milestone payment receivable related to technical progress       $ 2,500                
Research and development                 800 11,300 1,700  
Transaction price upfront fee received                     30,000  
Amended Collaboration Agreement 2019 | Juno Therapeutics                        
Agreement term   5 years                    
Extensions | item   2                    
Extension period   1 year                    
Potential development milestone payments   $ 27,500                    
Potential regulatory milestone payments   107,500                    
Potential licensed products milestone payments   60,000                    
Total transaction price                   102,500    
Amendment fee                   70,000    
License Agreement, Exercise Fee                   500    
Revenue recognized                 11,300 6,200    
Deferred revenue             90,700   90,700 32,000    
Deferred revenue, long-term             73,700   73,700 $ 96,300    
Transaction price upfront fee received   70,000                    
First development and commercialization license payment received   $ 500                    
Strategic Alliance | Allergan                        
Upfront fee received         $ 90,000              
Revenue recognized                 62,100      
Deferred revenue             $ 77,100   $ 77,100      
Number of Collaboration Development Programs | item 5                      
Option exercise payment received     $ 15,000                  
Sponsored Research Agreement | Broad                        
Research and development                     $ 12,500